Obesity is the leading risk factor for type 2 diabetes. Obesity causes increased levels of fatty acids and inflammation, leading to insulin resistance. In this touchENDOCRINOLOGY interview, Prof. Timothy Garvey (University of Alabama, Birmingham, AL, USA) discusses this risk of developing type 2 diabetes in people with obesity.
The abstract entitled: ‘Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
Questions:
- What is known about the risk of developing type 2 diabetes in people with obesity? (0:22)
Disclosures: Timothy Garvey discloses grant/research support from Eli Lilly, Epitomee, Novo Nordisk, Pfizer.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
